Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19 Study conducted at the Social Security Institute for Workers of the State of Chiapas, ISSTECH, Mexico
Authors : Alberto Cundapí Núñez; Gerardo Grajales Yuca; Jesús Miguel Leyva Cervantes; Ana Paola Rubiano Murcia; Marco Antonio Ordoñez Juárez; Jenner Josué Martínez
Volume/Issue : Volume 5 - 2020, Issue 7 - July
Google Scholar : http://bitly.ws/9nMw
Scribd : https://bit.ly/30yw7MH
DOI : 10.38124/IJISRT20JUL252
Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.
Abstract : This document sets out the results of a study aimed at estimating the therapeutic efficacy of ivermectin as an adjuvant in the treatment of COVID-19 patients treated at the Specialty Hospital Vida Mejor of the Institute of Social Security for Workers of the State of Chiapas, ISSTECH, Mexico. Ivermectin as an adjuvant in the treatment of COVID-19 patients is more effective (92%) outpatient patients. In critical hospitalized and severe hospitalized patients, ivermectin had a significant impact, both in improving patients' health and decreasing lethality
Keywords : Ivermectin, COVID-19, Efficacy.
Keywords : Ivermectin, COVID-19, Efficacy.